

Supplementary File 6 Cost-utility analysis - specific inputs and results

State	Utility/Utility decrement	Source
Age 18-29	0.86	Perneger, 2010
Age 30-39	0.86	
Age 40-49	0.84	
Age 50-59	0.81	
Age 60-69	0.8	
Age 70-79	0.76	
Age 80+	0.74	
Diagnosed CIN1	-0.01	Demarteau, 2011
Diagnosed CIN2/3	-0.01	
Cervical Cancer (1 st year)	-0.27	Korfage, 2009
Cervical Cancer (thereafter)	-0.06	

Scénario	QALY	Total cost (K€)	ICER (€/LY) vs current	Frontier
IndScr only*	16.4	122.6	Reference	Dominated
Pap/Pap-HPV	+9.54	+22.3	23,392	Dominated
Pap/p16Ki67	+11.18	+25.5	22,891	Dominated
HPV/Pap-3y	+14.99	+55.8	37,290	Dominated
HPV/Pap-5y	+14.76	-13.3	Dominant	Ext. Dominated
HPV/Pap-10y	+9.44	-73.4	Dominant	Reference
HPV/p16Ki67-5y	+17.06	+3.79	2,222	131,965
HPV/p16Ki67-10y	+11.88	-64.6	Dominant	36,468
p16Ki67/p16Ki67	+17.53	+160.7	91,703	3,302,932

*Reference for other scenarios. Extra-QALY per 10,000 women eligible for OS on a lifetime horizon. QALY: Quality Adjusted Life Years